📗 Cite This Artifact
AD Diagnostic and Imaging Companies
AD Diagnostic Imaging Companies
This page provides a comprehensive overview of companies developing diagnostic technologies and imaging solutions for Alzheimer's disease (AD) and related neurodegenerative conditions. The diagnostic imaging landscape has evolved significantly with advances in PET tracers, blood-based biomarkers, and AI-powered image analysis[@alzheimers2024].
Overview
...AD Diagnostic Imaging Companies
This page provides a comprehensive overview of companies developing diagnostic technologies and imaging solutions for Alzheimer's disease (AD) and related neurodegenerative conditions. The diagnostic imaging landscape has evolved significantly with advances in PET tracers, blood-based biomarkers, and AI-powered image analysis[@alzheimers2024].
Overview
The Alzheimer's diagnostic market encompasses several key technology areas:
- PET/SPECT Tracers: Radiopharmaceuticals for amyloid, tau, and alpha-synuclein imaging
- Blood-Based Biomarkers: Plasma and serum tests for p-tau, Abeta, and other neurodegenerative markers
- AI-Powered Imaging Analysis: Machine learning systems for MRI and PET image interpretation
- Digital Biomarkers: Wearable and digital platforms for cognitive assessment
PET and SPECT Tracer Companies
Life Molecular Imaging
[Life Molecular Imaging](/companies/life-molecular-imaging) is a German company specializing in PET tracers for neurodegenerative diseases. Key products include:
| Product | Target | Status |
|---------|--------|--------|
| Neuraceq® (Florbetaben F-18) | Beta-amyloid plaques | FDA approved (2014) |
| LMI 119 | Tau protein | Phase 2 |
| LMI 104 | Alpha-synuclein | Preclinical |
The company was acquired by Lantheus Holdings in 2024, strengthening its commercial capabilities[@lantheus2024].
Cerveau Technologies
Cerveau Technologies is developing next-generation PET tracers for tau pathology imaging in Alzheimer's disease and other tauopathies. Their lead program focuses on MK-6240, a high-affinity tau PET tracer.
| Tracer | Target | Development Stage |
|--------|--------|-------------------|
| MK-6240 | Tau neurofibrillary tangles | Phase 2/3 |
MK-6240 has demonstrated excellent properties for imaging tau pathology in AD patients and is being used in multiple therapeutic trials[@cerveau2024].
Other PET Tracer Developers
| Company | Focus Area | Key Products |
|---------|------------|--------------|
| AC Immune | Tau PET tracers | ACI-35.030 (vaccine), PET tracers in development |
| Roche | Amyloid and Tau | Gantenerumab (therapeutic), diagnostic tracers |
| Eisai | Amyloid PET | E2609 (elenbecestat), imaging biomarkers |
Blood-Based Biomarker Companies
Roche Diagnostics
[Roche](/companies/roche) offers the Elecsys platform, one of the most widely deployed automated biomarker measurement systems in clinical practice. Key assays include:
- Elecsys p-Tau181 — FDA 510(k) cleared for AD diagnosis
- Elecsys p-Tau217 — CE-IVD marked, FDA submission pending
- Elecsys Aβ42/40 Ratio — FDA 510(k) cleared for CSF testing
- Elecsys NfL — Neurofilament light chain for neurodegeneration
The Elecsys platform provides fully automated, high-throughput biomarker testing with excellent precision (intra-assay CV <5%)[@bittner2016].
Fujirebio
Fujirebio, a Japanese in vitro diagnostics company, offers the Lumipulse G platform with comprehensive Alzheimer's biomarker panels:
- Lumipulse G β-Amyloid 42/40 — CSF Aβ ratio for amyloid status
- Lumipulse G p-Tau181 — Phosphorylated tau for tau pathology
- Lumipulse G p-Tau217 — Advanced tau biomarker
In May 2025, the Lumipulse G pTau217/Aβ1-42 Plasma Ratio became the first FDA-approved plasma test for Alzheimer's disease biomarker evaluation[@fda2025].
Quanterix
Quanterix developed the Simoa (Single Molecule Array) technology, enabling ultra-sensitive biomarker detection with femtomolar sensitivity. The platform is widely used in research and pharmaceutical clinical trials.
| Assay | Application |
|-------|-------------|
| Simoa p-Tau181 | High-sensitivity plasma tau measurement |
| Simoa Aβ42/40 | Ultra-sensitive amyloid detection |
| Simoa NfL | Neurodegeneration marker |
AI-Powered Diagnostic Imaging Companies
icometrix
[icometrix](/companies/icometrix) is a Belgian medical AI company specializing in quantitative brain MRI analysis. Their FDA-cleared and CE-marked products include:
- icobrain — MS lesion segmentation and brain volume analysis
- icobrain AD — Alzheimer's disease hippocampal atrophy measurement
- icobrain tau — Tau pathology imaging biomarker (research use)
The company has partnerships with Biogen, Roche, and Merck for imaging biomarker development[@icometrix2024].
brainomix
brainomix develops AI-powered imaging analysis solutions for stroke and neurological conditions. Their platform provides:
- Automated CT and MRI analysis
- Volumetric measurements for brain atrophy tracking
- Integration with PACS systems for clinical workflow
Other AI Imaging Companies
| Company | Technology | Application |
|---------|------------|-------------|
| DeepMind (Google) | AI for MRI analysis | Brain age estimation, pathology detection |
| IXICO | AI imaging analytics | Clinical trial imaging endpoints |
| Radiology Partners | AI radiology platform | Large-scale imaging analysis |
Market Landscape
Global AD Diagnostic Market
| Segment | Market Size (2024) | Projected Growth |
|---------|-------------------|------------------|
| PET Imaging | $1.2B | 8% CAGR |
| Blood Biomarkers | $800M | 15% CAGR |
| AI Imaging Analytics | $400M | 20% CAGR |
Key Trends
Company Profiles
Life Molecular Imaging
Headquarters: Berlin, Germany Parent Company: Lantheus Holdings Founded: 2013 Focus: PET tracers for neurodegenerative diseases
Key products: Neuraceq® (florbetaben F-18), LMI 119 (tau), LMI 104 (alpha-synuclein)
icometrix
Headquarters: Leuven, Belgium Founded: 2011 Focus: AI-powered MRI analysis
Key products: icobrain, icobrain AD, icobrain tau
Roche Diagnostics
Headquarters: Basel, Switzerland Focus: In vitro diagnostics, biomarker assays
Key products: Elecsys p-Tau181, Elecsys p-Tau217, Elecsys Aβ42/40
Related Pages
- [AD Pipeline Companies](/companies/ad-pipeline-companies) — Therapeutic development companies](/companies/ad-pipeline-companies)
- [Alzheimer's Disease](/diseases/alzheimers-disease) — Disease overview
- [PET Imaging](/diagnostics/pet-imaging) — PET diagnostic methods](/diagnostics)
- [Tau PET Imaging](/diagnostics/tau-pet-imaging) — Tau imaging techniques](/diagnostics)
- [Plasma Biomarkers](/diagnostics/plasma-biomarkers) — Blood-based biomarker tests](/diagnostics)
- [Neuroimaging](/diagnostics/neuroimaging) — Imaging methods overview](/diagnostics)
- [Roche Elecsys](/diagnostics/roche-elecsys) — Roche diagnostic platform](/diagnostics)
- [Fujirebio Lumipulse](/diagnostics/fujirebio-lumipulse-g) — Fujirebio diagnostic platform
See Also
- [Companies Overview](/companies/overview) — Main company index
- [Companies Rankings](/companies/rankings) — Company rankings](/companies/rankings)
- [Investment Landscape](/investment) — Investment in AD diagnostics
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | companies-ad-diagnostic-imaging-companies |
| kg_node_id | None |
| entity_type | company |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-ff953ace4a4e |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'companies-ad-diagnostic-imaging-companies'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-companies-ad-diagnostic-imaging-companies?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[AD Diagnostic and Imaging Companies](http://scidex.ai/artifact/wiki-companies-ad-diagnostic-imaging-companies)
http://scidex.ai/artifact/wiki-companies-ad-diagnostic-imaging-companies